BioSpace News Archive

Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that its Belgian subsidiary Aligos Belgium BV has been awarded a €1.8M grant by the Flemish Agency for Innovation and Entrepreneurship (VLAIO) to support a nonclinical research project related to combination thera

- Company nominates OPA1 as the next preclinical target for its proprietary TANGO approach to treating the underlying cause of severe genetic diseases – - OPA1 protein deficiency is the leading cause of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder –

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today reported financial results for the quarter ended September 30, 2020

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN® will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference

The University of Texas MD Anderson Cancer Center has named 10 early-career faculty members to the 2020 class of Andrew Sabin Family Fellows.

Neuronasal, Inc., a clinical-stage pharmaceutical company developing new treatments for acute mild traumatic brain injury in partnership with ATAI, announced that it has completed its pilot study intended to show nose-to-brain delivery of N-acetylcysteine in healthy volunteers.

Ten Additional Technology Leaders Join Founding Members to Together Advance Industry Roadmap, Set Stage for Widespread Adoption of New Long-term Storage Option

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced third quarter 2020 financial results and provided an operational update.

Inari Medical, Inc., a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the appointment of Kevin Strange as VP of Strategy and Business Development, and Angela Ahmad as General Counsel.

Early Interim Data for TRIDENT-1 Phase 2 Study of Repotrectinib and Second Drug Candidate, TPX-0022,Recently Presented